OA12056A - Use of the NN'dibenzylthiourea compound as a medicament - Google Patents

Use of the NN'dibenzylthiourea compound as a medicament Download PDF

Info

Publication number
OA12056A
OA12056A OA1200200099A OA1200200099A OA12056A OA 12056 A OA12056 A OA 12056A OA 1200200099 A OA1200200099 A OA 1200200099A OA 1200200099 A OA1200200099 A OA 1200200099A OA 12056 A OA12056 A OA 12056A
Authority
OA
OAPI
Prior art keywords
hydroxyl radical
human
treatment
diseases
disease
Prior art date
Application number
OA1200200099A
Other languages
French (fr)
Inventor
Wandji Thomas Dr
Original Assignee
Wandji Thomas Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wandji Thomas Dr filed Critical Wandji Thomas Dr
Priority to OA1200200099A priority Critical patent/OA12056A/en
Priority to AU2003232698A priority patent/AU2003232698A1/en
Priority to PCT/OA2003/000002 priority patent/WO2003084523A1/en
Publication of OA12056A publication Critical patent/OA12056A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention concerns the use of a compound chemically called N,N'-dibenzyl-thiourea, a biological antioxidant extracted from a plant of the family of Pentadiplandraceae: Pentadiplandra brazzeana, brazzeana variety for preventive treatment of diseases mediated in human subjects or animals by the action of the hydroxyl radical (OH DEG ). The hydroxyl radical which exists naturally in human subjects bears an unpaired orbital electron. It is aggressive and destroys human and animal cells. There results cell degeneration and death, hence the occurrence in human subjects of diseases such as Parkinson's disease and Alzheimer's disease. N,N'-dibenzyl-thiourea eliminates the hydroxyl radical (OH DEG ) from the human or animal system. This treatment should be preventive and curative in targeted subjects such as children and old people.

Description

1 2056.1 2056.

La présente invention est relative à l'utilisation de N'N DIBENZYLTHIOUREE,compose extrait du PENTADEPLANDRA BRAZZEANA variété BRAZZEANAdans le traitement thérapeutique de l'homme ou de l'animal.The present invention relates to the use of N'N DIBENZYLTHIOUREE, compound extracted from PENTADEPLANDRA BRAZZEANA variety BRAZZEANAdans the therapeutic treatment of humans or animals.

INDICATIONS THERAPEUTIQUES -........ .. .. - - ,THERAPEUTIC INDICATIONS -........ .. .. - - ,

Ce médicament est indiqué dans le traitement de toutes les maladi.es dues à laprésence du radical libre oxygénée ( radical hydroxyl : OH°) dans l'organismehumain ou animal, notamment : Maladie D'ALSHEIMER, Maladie dePARKINSON, Cancer des personnes du 3eme âge et de l’enfant, Avitaminoses'sévères chez l'adulte et enfant (kwashiorkor), Maladie cardrovasculaire, Diabète etcomplications, Vieillissement de l'organisme, Maladies dues au tabagisme.This medicinal product is indicated for the treatment of all diseases caused by the presence of the oxygenated free radical (hydroxyl radical: OH °) in the human or animal organism, in particular: ALSHEIMER'S DISEASE, PARKINSON'S DISEASE, Cancer of the elderly and children, Vitamin A deficiency in adults and children (kwashiorkor), Cardrovascular disease, Diabetes and complications, Aging of the body, Diseases caused by smoking.

Le radical hydroxyl OH° est responsable de l'altération de l'état et du fonctionnement de nombreuses cellules. 11 entraîne la dégénérescence des cellules indépendamment de leur appartenance.Jusqu'à ce jour les médicaments utilisés dans la thérapeutique de ces maladiesétaient destinés à combattre uniquement leurs symptômes. C'est ainsi qu'on utilise les dopaminergiques (apomorphine), les tranquillisants, lessomnifères, les antidépresseurs, les neuroleptiques, les oxygénateurs,vasodilatateurs.The hydroxyl radical OH ° is responsible for the alteration of the state and the functioning of many cells. It induces the degeneration of cells irrespective of their membership. Until now the drugs used in the treatment of these diseases were intended to combat only their symptoms. Thus dopaminergics (apomorphine), tranquillizers, lesser substances, antidepressants, neuroleptics, oxygenators and vasodilators are used.

Le traitement par la N'N DIBENZYLTHIOUREE est destiné à débarrasser,l'organisme du radical hydroxyl (OH°). Ce traitement préventif et curatif régénèreles tissus morts et rétablit le fonctionnement normal des cellules. ·Treatment with N'N DIBENZYLTHIOUREE is intended to rid the body of the hydroxyl radical (OH °). This preventive and curative treatment regenerates dead tissue and restores normal cell function. ·

Les radicaux libres sont des atomes, des groupes d'atomes, ou des moléculespossédant un électron non apparié ou célibataire sur l'orbital externe . La tendanceà apparier cet électron orbital externe explique leur agressivité biologique.Free radicals are atoms, groups of atoms, or molecules with an unpaired or single electron on the outer orbital. The tendency to match this external orbital electron explains their biological aggressivity.

En effet, en arrachant cet électron à une autre molécule, dès lors transformé à sontour en radical libre, ils provoquent des réactions en chaîne aboutissant àl'altération de nombreuses structures cellulaires. L'apparition du radical hydroxyl dans l'organisme se passe tle la rrianière suivante :L'eau oxygénée apparaît naturellement dans l'organisme mais elle estrégulièrement détruite par la catalase, de sorte que la réaction de formation decette eau oxygénée à partir de l'eau et de l'oxygène est réversible. H2O2 ' <.....— H2O + Ά O2 (sous l'action de la catalase). * · 1 1 2056Indeed, by tearing this electron to another molecule, since then converted to estour free radical, they cause chain reactions leading to the alteration of many cell structures. The appearance of the hydroxyl radical in the organism occurs in the following way: Hydrogen peroxide appears naturally in the organism but it is regularly destroyed by catalase, so that the reaction of formation of this oxygenated water from the water and oxygen is reversible. H2O2 '<.....- H2O + Ά O2 (under the action of catalase). * 1 1 2056

Chez l'enfant de 0 à 5 ans et personne âgée on constate, une insuffisance de lasécrétion de la catalase et la réaction ci-dessus n'est plus réversible - l'eauoxygénée subit la réaction, de fenton au cours de laquelle il se décompose en un 'banal ion OH" et un radical hydroxyl OH° très réactif. .. AIn the child of 0 to 5 years old and senior, there is a deficiency of catalase secretion and the above reaction is no longer reversible - the oxygenated water undergoes the reaction, fenton during which it decomposes into a "common OH ion" and a hydroxyl radical OH ° very reactive.

Cette réaction se fait en présence de Fe2+ présent dans l'organisme humain ou.animal .This reaction is in the presence of Fe2 + present in the human or animal organism.

Fe2+ + H2O2->Fe3+ + ΟΗΓ + OH° L'apparition radical OH° dans l'organisme peut aussi être induite directement parla chaleur, la lumière ou radiation énergétique. L'altération de nombreusesstructures cellulaires porte généralement sur les noyaux : modification desstructures des éléments nobles particulièrement des acides ribonucléiques etdésoxyribonucléiques ainsi que sur les doubles liaisons des acides gras polyinsaturés de la membrane cellulaire.Fe2 + + H2O2-> Fe3 + + ΟΗΓ + OH ° The OH ° radical appearance in the body can also be directly induced by heat, light or energetic radiation. The alteration of many cellular structures is generally related to the nuclei: modification of the structures of noble elements, particularly of ribonucleic and deoxyribonucleic acids, as well as on the double bonds of the polyunsaturated fatty acids of the cell membrane.

Les maladies constituant les indications thérapeutiques chez l'homme ou chezl'animal de la NN' DIBENZYLTHIOUREE sont provoquées dans l'organismepar l'agressivité du radical hydroxyl.The diseases constituting the therapeutic indications in man or in the animal of NN 'DIBENZYLTHIOUREE are caused in the body by the aggressivity of the hydroxyl radical.

La lutte contre ces maladies consiste en l'utilisation des molécules biologiques-pouvant donner un atome d'hydrogène au radical hydroxyl. Pour le transformer eneau (H2O). Par exemple : la NN’ DIBENZILTHIOUREE donne les H mobiles ouhydrogènes mobiles au radical hydroxyl selon le mécanisme suivant :The fight against these diseases consists of the use of biological molecules that can give a hydrogen atom to the hydroxyl radical. To transform it into water (H2O). For example: NN 'DIBENZILTHIOUREE gives the mobile H or mobile hydrogen to the hydroxyl radical according to the following mechanism:

S +4HO°S + 4HO °

POLYMEREPOLYMER

STABLESTABLE

Le médicament, objet de la présente invention ayant poqr principe actif la NN’DIBENZILTHIOUREE extraite du PENTAPLANDRA BRAZZEANAVARIETE BRAZZEANA fournit les "H" au radical hydroxyl OH°, le 2 1 2056 transformant ainsi en eau (H2O) qui s'élimine de l'organisme par voie urinaire et lepolymère formé qui est neutre s'élimine aussi par voie urinaire. ? L'avantage de cet antioxydant est qu'il est biologique. * 5 La NN' DIBENZYTHIOUREE n'est pas toxique à part son action ocytocique sur l'utérus gravide.The medicinal product which is the subject of the present invention having the active ingredient NN'DIBENZILTHIOUREE extracted from PENTAPLANDRA BRAZZEANAVARIETE BRAZZEANA supplies the "H" to the hydroxyl radical OH °, thereby transforming it into water (H2O) which is eliminated from the urinary organism and the formed polymer which is neutral is also eliminated by the urinary tract. ? The advantage of this antioxidant is that it is organic. * 5 NN 'DIBENZYTHIOUREE is not toxic apart from its oxytocic action on the pregnant uterus.

Ce médicament est présenté sous les formes galéniques suivantes : 10 SiropThis medicine is presented in the following dosage forms: 10 Syrup

COMPOSITION - NN' DIBENZYL THIOUREE 108 mg 15 Excipient : sirop saccharose QSP 250 mlCOMPOSITION - NN 'DIBENZYL THIOUREE 108 mg 15 Excipient: syrup sucrose QSP 250 ml

POSOLOGIE ADULTE : 2 cuillerées à soupe Matin et soir 20 ' · ENFANT : 2 cuillerées à café Matin et soir D'autres formes par voie orale (gélules, comprimés) et voie rectale (suppositoire)peuvent être fabriquées. Il faut simplement protéger la NN' 25 DIBENZYLTHIOUREE contre l'oxygène de l'air. 3ADULT DOSAGE: 2 tablespoons Morning and evening 20 '· CHILD: 2 teaspoons Morning and evening Other oral forms (capsules, tablets) and rectal route (suppository) can be made. It is simply necessary to protect the NN 'DIBENZYLTHIOUREE against the oxygen of the air. 3

Claims (3)

1 2056 REVENDICATIONS 1) Utilisation du composé NN' DIBENZYLTHIOUREE pour la préparation du 3médicament dans le traitement des maladies, notamment des maladies résultant de ûl'altération de l'état ou du fonctionnement des cellules humaines ou animales parle radical hydroxyl. 51) Use of the compound NN 'DIBENZYLTHIOUREE for the preparation of 3medicament in the treatment of diseases, including diseases resulting from the alteration of the state or operation of human or animal cells by hydroxyl radical. 5 2) Médicament suivant la revendication 1 caractérisé en ce que sa composition estde: - NN’ DIBENZYLTHIOUREE 108 mg - Sirop de saccharose QSP - 250 ml 102) A medicament according to claim 1 characterized in that its composition isde - NN 'DIBENZYLTHIOUREE 108 mg - sucrose syrup QSP - 250 ml 10 3) Médicament selon les revendications 1 et 2 caractérisé en ce qu'il est obtenu sousles formes galéniques suivantes : - Sirop, gélule, suppositoire comprimé. iT 43) Drug according to claims 1 and 2 characterized in that it is obtained in the following galenic forms: - syrup, capsule, suppository tablet. iT 4
OA1200200099A 2002-04-05 2002-04-05 Use of the NN'dibenzylthiourea compound as a medicament OA12056A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
OA1200200099A OA12056A (en) 2002-04-05 2002-04-05 Use of the NN'dibenzylthiourea compound as a medicament
AU2003232698A AU2003232698A1 (en) 2002-04-05 2003-03-27 Use of a n,n'-dibenzyl-thiourea as medicine
PCT/OA2003/000002 WO2003084523A1 (en) 2002-04-05 2003-03-27 Use of a n,n'-dibenzyl-thiourea as medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
OA1200200099A OA12056A (en) 2002-04-05 2002-04-05 Use of the NN'dibenzylthiourea compound as a medicament

Publications (1)

Publication Number Publication Date
OA12056A true OA12056A (en) 2003-10-24

Family

ID=34102066

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200200099A OA12056A (en) 2002-04-05 2002-04-05 Use of the NN'dibenzylthiourea compound as a medicament

Country Status (3)

Country Link
AU (1) AU2003232698A1 (en)
OA (1) OA12056A (en)
WO (1) WO2003084523A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009042693A1 (en) * 2009-09-23 2011-03-24 Merck Patent Gmbh Materials for electronic devices
FR2988000A1 (en) * 2012-03-16 2013-09-20 Thomas Wandji Combination of propylene methoxy-4-phenyl-2-methyl-2-isothiocyanate, N,N-dibenzylthiourea in the form of hydroalcoholic solution (anti oxidant), beta-sitosterol and stigmasterol as an antiviral drug, for killing human and animal viruses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2166349A1 (en) * 1972-01-04 1973-08-17 Wandji Thomas Difeu alkaloids - for treating diarrhoea, peptic ulcer anorexia, as a diuretic, as a sclerosing agent
FR2693106A1 (en) * 1992-10-02 1994-01-07 Wandji Thomas Extract contg. aromatic isothiocyanate, thiocarbamate, and thiourea - for the treatment of functional metrorrhagia, and as a venous tonic and free radical trap

Also Published As

Publication number Publication date
AU2003232698A1 (en) 2003-10-20
WO2003084523A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
Holdiness Clinical pharmacokinetics of N-acetylcysteine
KR100245482B1 (en) Active oxygen scavenger
JP2006515290A (en) Witania somnifera composition, method for obtaining it, and pharmaceutical formulations, nutritional agents and personal care formulations thereof
FR2508798A1 (en) ANTHRAQUINONIC DERIVATIVES FOR THE TREATMENT OF ARTHRITIS
JP2001064192A (en) Migration inhibitor for langerhans cell and antigen presentation inhibitor
JPH0714867B2 (en) Pharmaceutical composition for suppressing aging
EP1464330B1 (en) antiallergic composition containing oligosaccharides in combination with a saponine or a basic aminoacid, for topical administration or for inhalation
CA2802154C (en) A method for preparation of highly pure asiaticoside composition from centella asiatica and a method of use thereof
Li et al. Lipoic acid protects gastric mucosa from ethanol-induced injury in rat through a mechanism involving aldehyde dehydrogenase 2 activation
Jung et al. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis
RU2104032C1 (en) Method of potentiation of medicinal agent curative effect
US5712259A (en) NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
OA12056A (en) Use of the NN&#39;dibenzylthiourea compound as a medicament
KR20010082721A (en) Fatty-acid containing composition
Briffa et al. Photochemotherapy in psoriasis: a review
KR102152407B1 (en) Cosmetic composition containing phycocyanobilin and its derivative derived from spirulina
US20060058392A1 (en) Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase
RU2154480C1 (en) Method of treatment of patients with psoriasis in combination with chronic opisthorchiasis
RU2556962C1 (en) Method of treating chronic opisthorchiasis in patients with rosacea
JPS58501911A (en) Rheumatoid arthritis treatment drug
WO2017137767A1 (en) Anti-neurodegenerative disease formulation containing apocynin and paeonol
US20060167104A1 (en) Method for extracting a novel compound from the root of a plant of the pentadiplandraceae family and use of N,N&#39;-dibenzylthiourea as a medicine
FR2569563A1 (en) Formulation based on benzoylecgonine or benzoylnorecgonine for the treatment of arthritis
Panda et al. Zinc in Ayurvedic herbo-mineral products
RU2149013C1 (en) Method and biostimulation means for treating somatic diseases